| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Xalkori | |
| 3 | Generic Name | crizotinib | |
| 4 | Mechanism | ALK kinase inhibitor. MET/ROS activity as well. | |
| 5 | Indication | NSCLC with ALK mutations | |
| 6 | Clinical Trials | ||
| 7 | Phase III PROFILE 1007 | ||
| 8 | Xalkori vs pemetrexed/docetaxel in ALK+ NSCLC. | ||
| 9 | PFS primary endpoint met 6/19/12. |